[From spondyloarthropathies to spondyloarthritis: towards a new terminology for an early diagnosis and new therapeutic interventions?].
Inserm CBT-506, centre d'investigation clinique biothérapie, pôle recherche, CHRU, place Saint-Jacques, 25000 Besançon, France; Rhumatologie, pôle PACTE (pathologies aiguës chroniques transplantation éducation), CHRU, 25000 Besançon, France; UPRES EA 4266 « Agents pathogènes et inflammation », département universitaire de thérapeutique, SFR FED 4234, université de Franche-Comté, Besançon, France. Electronic address: etoussirot@chu-besancon.fr.
É
É
Toussirot
D000906:Antibodies / Q000627:therapeutic use; D042241:Early Diagnosis; D006801:Humans; D008279:Magnetic Resonance Imaging; D011237:Predictive Value of Tests; D025241:Spondylarthritis / Q000145:classification* / Q000175:diagnosis / Q000628:therapy*; D025242:Spondylarthropathies / Q000145:classification* / Q000175:diagnosis / Q000628:therapy*; D009626:Terminology as Topic; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D000906:Antibodies; D014409:Tumor Necrosis Factor-alpha
ASAS; Diagnosis; Diagnostic; Imagerie par résonance magnétique nucléaire (IRM); Magnetic resonance imaging (MRI); Specificity; Spondyloarthrite; Spondyloarthritis; Spécificité